Guidance for Industry

Regulation of Mosquito-Related Products

Draft Guidance

This guidance document is being distributed for comment purposes only.

Submit comments on this draft guidance by the date provided in the Federal Register notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions regarding this draft document, contact Laura R. Epstein, Center for Veterinary Medicine (HFV-1), Food and Drug Administration, 7519 Standish Place, Rockville, MD 20855, 301-796-8558, e-mail: laura.epstein@fda.hhs.gov

Additional copies of this draft guidance document may be requested from the Policy and Regulations Staff (HFV-6), Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Place, Rockville, MD 20855, and may be viewed on the Internet at either http://www.fda.gov/AnimalVeterinary/default.htm or http://www.regulations.gov.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Veterinary Medicine
January 2017
## Table of Contents

I. INTRODUCTION ........................................................................................................... 3  
II. BACKGROUND .......................................................................................................... 3  
   A. New Animal Drugs .......................................................................................... 3  
III. DISCUSSION ........................................................................................................... 4  
   A. Scope of Guidance ......................................................................................... 4  
   B. Regulation of Mosquito-Related Products ...................................................... 4  
   C. Guidance for Sponsors/Manufacturers of Products Intended for use in Mosquitoes ......................................................... 5  
IV. Contact Information ............................................................................................... 6
I. INTRODUCTION

This guidance provides information for industry and other stakeholders regarding regulatory oversight of articles, including substances, for use in or on mosquitoes (“mosquito-related products”). We are providing this guidance to clarify circumstances under which such products are regulated by the Food and Drug Administration (FDA) as new animal drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and other circumstances under which such products are regulated by the Environmental Protection Agency (EPA) as pesticides under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency’s guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

Both FDA and EPA regulate products intended for use in or on animals. FDA is charged with protecting the public health by, among other things, ensuring that animal drugs are safe and effective [21 U.S.C. §393(b)(2)(B)]; under FIFRA, EPA is charged with protecting human health and the environment by ensuring registered pesticide products, when used according to the label directions, result in no unreasonable adverse effects to man or the environment. [7 U.S.C. § 136a(c)(5)].

A. New Animal Drugs

The FD&C Act defines the term “drug” as, among other things, “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals” and “articles (other than food) intended to affect the structure or any function of the body of man or other animals.” [21 U.S.C. §321(g)(1)]. With very limited exceptions for animal drugs that are generally recognized as safe and effective or are subject to a “grandfather” clause, the FD&C Act defines drugs that are intended for use for animals as “new animal drugs.” As such, these drugs are subject to applicable pre-market approval and/or other review requirements. [21 U.S.C. §321(v); 21 U.S.C. §360b; 21 U.S.C. §360ccc; 21 U.S.C. §360ccc-1].
B. Pesticides

FIFRA defines the term “pesticide” to mean, in part, “(1) any substance or mixture of substances intended for preventing, destroying, repelling, or mitigating any pest…except that the term ’Pesticide’ shall not include any article that is a ‘new animal drug’ within the meaning of section 321([v]) of title 21…” [7 U.S.C. §136(u)] Generally speaking, pesticides must be registered with EPA prior to distribution or sale, unless they are otherwise excluded or exempted from regulation (e.g., they meet the specific conditions or criteria in 40 CFR § 152.6; or they qualify for an exemption as, for instance, a minimum risk pesticide under 40 CFR § 152, Subpart B).

III. DISCUSSION

A. Scope of Guidance

This guidance provides information for industry and other stakeholders regarding regulatory oversight of mosquito-related products. This guidance is important in light of the public health urgency of countering the spread of mosquito-borne disease, such as that caused by the Zika virus. Vector control is a critical element of the effort to combat the spread of mosquito-borne disease.¹ Novel mosquito control technologies have gained greater attention as an element of this effort; however, there has been some confusion with respect to FDA’s and EPA’s respective jurisdiction over such mosquito-related products.

Given the public health implications of mosquito control, FDA is providing this guidance to clarify the regulatory oversight of mosquito-related products, including but not limited to those produced through biotechnology.²

B. Regulation of Mosquito-Related Products³

The FD&C Act defines “articles (other than food) intended to affect the structure or any function of the body of man or other animals” as new animal drugs. However, mosquitoes also fall within the FIFRA definition of “pest.”⁴ Pesticide products for mosquitoes affect the structure or function of the body of the mosquito. Before 1975, FDA and EPA each had authority to regulate

² We also note that FDA (along with EPA and USDA) has committed to clarifying how the U.S. Federal Government intends to regulate genetically engineered insects. National Strategy for Modernizing the Regulatory System for Biotechnology Products, released by the White House Office of Science and Technology Policy, September 16, 2016.
³ Developers may need to comply with additional requirements for import or interstate movement of certain mosquito-related products. To ensure you are in compliance with applicable requirements, contact APHIS at https://www.aphis.usda.gov/aphis/ourfocus/biotechnology/sa_contact_brs/ct_contact_brs; and CDC at https://www.cdc.gov/phpr/ipp/index.htm.
⁴ FIFRA defines a “pest” broadly to include “(1) any insect, rodent, nematode, fungus, weed, or (2) any other form of terrestrial or aquatic plant or animal life or virus, bacteria, or other micro-organism (except viruses, bacteria, or other micro-organisms on or in living man or other animals).” 7 U.S.C. § 136(t).
substances that controlled mosquito population if they met both the definition of "new animal drug" under the FD&C Act and the definition of "pesticide" under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). Because of concern that this dual jurisdiction created regulatory burden and confusion about which Agency had primary jurisdiction, Congress amended FIFRA’s definition of "pesticide" in 1975 to exclude any article that is a “new animal drug” within the meaning of the FD&C Act. Since the FIFRA definition of pesticide was amended in 1975, EPA has registered, as pesticides, articles that control the population of mosquitoes by killing them or interfering with their reproduction, which is consistent with FDA’s and EPA’s general agreement that articles or categories of articles that control the population of mosquitoes are most appropriately regulated as pesticides.

Given this history, FDA is clarifying that the phrase “articles (other than food) intended to affect the structure or any function of the body of man or other animals” in the FD&C Act’s drug definition [21 U.S.C. 321 (g)(1)(C)] does not include articles intended to function as pesticides by preventing, destroying, repelling or mitigating mosquitoes for population control purposes. FDA believes that this interpretation is consistent with congressional intent and provides a rational approach for dividing responsibilities between FDA and EPA in regulating mosquito-related products.

1. Examples of New Animal Drugs
   a. Products intended to reduce the virus/pathogen load within a mosquito, including reduction in virus/pathogen replication and spread within the mosquito and/or reduction in virus/pathogen transmissibility from mosquitoes to humans.
   b. Products intended to prevent mosquito-borne disease in humans or animals.

2. Example of Pesticide Products
   a. Products intended to reduce the population of mosquitoes (for example, by killing them at some point in their life cycle, or by interfering with their reproduction or development)⁵.

C. Guidance for Sponsors/Manufacturers of Products Intended for use in Mosquitoes

FDA encourages sponsors of mosquito-related products other than those that are intended to prevent, destroy, repel, or mitigate mosquitoes to control population to contact FDA early in the development process. If there are any questions with respect to whether the product should be regulated as a new animal drug by FDA, or is more appropriately regulated by EPA as a pesticide (e.g., the product is intended to reduce the population of mosquitoes and does not make a disease prevention claim), FDA may consult EPA or suggest a joint meeting with the sponsor and both agencies to discuss appropriate pathways to market.

⁵ This is true whether the product is a traditional chemical product or involves a different technology (e.g., a recombinant DNA construct or bacteria intended to reduce the population of mosquitoes).
IV. Contact Information

If you have any questions about how this interpretation may affect your regulated products, or products you have under development, you should contact the following FDA and EPA personnel:

**FDA:**
Laura R. Epstein  
Center for Veterinary Medicine (HFV-1)  
Food and Drug Administration  
7519 Standish Pl.  
Rockville, MD 20855  
301-796-8558

**EPA:**
Elizabeth A. Milewski, Ph.D.  
Biopesticides and Pollution Prevention Division  
Office of Pesticide Programs  
Environmental Protection Agency  
1200 Pennsylvania Avenue NW  
Washington DC 20460  
703-347-0400

Christopher A. Wozniak, Ph.D.  
Biopesticides and Pollution Prevention Division  
Office of Pesticide Programs  
Environmental Protection Agency  
1200 Pennsylvania Avenue NW  
Washington DC 20460  
703-308-4043